Severe inflammatory myopathy in a pulmonary carcinoma patient treated with Pembrolizumab: An alert for myologists

L. Peverelli; A. De Rosa; E. Domina; P. Ciscato; G. Sita; D. Velardo; G. P. Comi

doi:10.3233/JND-200504

Severe inflammatory myopathy in a pulmonary carcinoma patient treated with Pembrolizumab: An alert for myologists

L. Peverelli, A. De Rosa, E. Domina, P. Ciscato, G. Sita, D. Velardo, G. P. Comi

Fondazione IRCCS Ca' Granda- Ospedale Maggiore Policlinico

Research output: Contribution to journal › Article › peer-review

Abstract

Immune-related adverse events (irAE) during the administration of immune-checkpoint inhibitors (ICIs) become more evident due to the increased use of these therapies. To remind the importance of early recognition of this phenomenon, we report a paradigmatic case characterized by severe systemic inflammatory myopathy and severe cardiac involvement that abruptly precipitated in an untoward ending after one single dose of Pembrolizumab.

Original language	English
Pages (from-to)	511-514
Number of pages	4
Journal	Journal of Neuromuscular Diseases
Volume	7
Issue number	4
DOIs	https://doi.org/10.3233/JND-200504
Publication status	Published - 2020

Keywords

immune-checkpoint inhibitors
immune-correlated adverse events
inflammatory myopathy
Pembrolizumab
pulmonary carcinoma

ASJC Scopus subject areas

Neurology
Clinical Neurology

Access to Document

10.3233/JND-200504

Fingerprint Dive into the research topics of 'Severe inflammatory myopathy in a pulmonary carcinoma patient treated with Pembrolizumab: An alert for myologists'. Together they form a unique fingerprint.

Cite this

@article{a3f7854b90e44a48b6a4ac531f14c969,

title = "Severe inflammatory myopathy in a pulmonary carcinoma patient treated with Pembrolizumab: An alert for myologists",

abstract = "Immune-related adverse events (irAE) during the administration of immune-checkpoint inhibitors (ICIs) become more evident due to the increased use of these therapies. To remind the importance of early recognition of this phenomenon, we report a paradigmatic case characterized by severe systemic inflammatory myopathy and severe cardiac involvement that abruptly precipitated in an untoward ending after one single dose of Pembrolizumab.",

keywords = "immune-checkpoint inhibitors, immune-correlated adverse events, inflammatory myopathy, Pembrolizumab, pulmonary carcinoma",

author = "L. Peverelli and {De Rosa}, A. and E. Domina and P. Ciscato and G. Sita and D. Velardo and Comi, {G. P.}",

year = "2020",

doi = "10.3233/JND-200504",

language = "English",

volume = "7",

pages = "511--514",

journal = "Journal of Neuromuscular Diseases",

issn = "2214-3599",

publisher = "IOS Press",

number = "4",

}

TY - JOUR

T1 - Severe inflammatory myopathy in a pulmonary carcinoma patient treated with Pembrolizumab

T2 - An alert for myologists

AU - Peverelli, L.

AU - De Rosa, A.

AU - Domina, E.

AU - Ciscato, P.

AU - Sita, G.

AU - Velardo, D.

AU - Comi, G. P.

PY - 2020

Y1 - 2020

N2 - Immune-related adverse events (irAE) during the administration of immune-checkpoint inhibitors (ICIs) become more evident due to the increased use of these therapies. To remind the importance of early recognition of this phenomenon, we report a paradigmatic case characterized by severe systemic inflammatory myopathy and severe cardiac involvement that abruptly precipitated in an untoward ending after one single dose of Pembrolizumab.

AB - Immune-related adverse events (irAE) during the administration of immune-checkpoint inhibitors (ICIs) become more evident due to the increased use of these therapies. To remind the importance of early recognition of this phenomenon, we report a paradigmatic case characterized by severe systemic inflammatory myopathy and severe cardiac involvement that abruptly precipitated in an untoward ending after one single dose of Pembrolizumab.

KW - immune-checkpoint inhibitors

KW - immune-correlated adverse events

KW - inflammatory myopathy

KW - Pembrolizumab

KW - pulmonary carcinoma

UR - http://www.scopus.com/inward/record.url?scp=85091469836&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85091469836&partnerID=8YFLogxK

U2 - 10.3233/JND-200504

DO - 10.3233/JND-200504

M3 - Article

C2 - 32623405

AN - SCOPUS:85091469836

VL - 7

SP - 511

EP - 514

JO - Journal of Neuromuscular Diseases

JF - Journal of Neuromuscular Diseases

SN - 2214-3599

IS - 4

ER -